# Rakovina Therapeutics

Type: Company (RKV)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/rakovina-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/rakovina-therapeutics

## Timeline

- **2026-Q2 (estimated)**: Closing of Private Placement — Expected completion of the $1.0 million common share offering and debenture issuance.
- **2026-02-21**: Financing Upsized — Rakovina announces an increase in its funding round to $2.0 million due to investor demand.
- **2026 (estimated)**: Operational Milestone — Anticipated use of funds for lead candidate advancement or IND-enabling studies.

## Recent coverage (1 stories)

### Rakovina Therapeutics Upsizes Financing to $2M to Fuel Oncology Pipeline
2026-02-21 03:07:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Rakovina Therapeutics has announced an upsized financing package totaling up to $2.0 million, split between convertible debentures and a private placement. The capital injection is earmarked for near-term operations as the company advances its DNA-damage response (DDR) oncology programs.
Full story: https://getbiobrief.com/story/rakovina-therapeutics-upsized-financing-oncology

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.